TearLab (NASDAQ:TEAR) +6.2% premarket after Canaccord Genuity initiates coverage with a Buy rating a $6 price target, noting the company offers the first point of care instrument that can quantitatively measure and diagnose dry eye disease. The firm says U.S. market potential includes 50,000 eye specialists who see on average six dry eye patients per day, equaling a $1.8B opportunity.